Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7773300 | 0.83 | KCNH2 (0.52) | KCNH2SCN3ACYP2C19DPP4 | |
| SCHEMBL2038087 | 0.83 | KCNH2 (0.56) | KCNH2SLC6A3SCN3ACYP2C19DPP4 | |
| SCHEMBL7769177 | 0.83 | KCNH2 (0.52) | KCNH2SCN3ACYP2C19DPP4 | |
| SCHEMBL7769176 | 0.83 | KCNH2 (0.52) | KCNH2SCN3ACYP2C19DPP4 | |
| SCHEMBL7775249 | 0.83 | KCNH2 (0.52) | KCNH2SCN3ACYP2C19DPP4 | |
| SCHEMBL2036845 | 0.83 | SLC6A3 (0.51) | KCNH2SLC6A3SCN3ATP53MDM2 | |
| SCHEMBL29788146 | 0.83 | SLC6A3 (0.51) | KCNH2SLC6A3SCN3ATP53MDM2 | |
| SCHEMBL2036846 | 0.83 | SLC6A3 (0.51) | KCNH2SLC6A3SCN3ATP53MDM2 | |
| SCHEMBL197425 | 0.82 | KCNH2 (0.56) | KCNH2SCN3ACYP2C19DPP4 | |
| SCHEMBL5696388 | 0.82 | KCNH2 (0.56) | KCNH2SCN3ACYP2C19DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995084-B2 | Pyrrolidine derivative | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-05-04 | — | — | US | disclosed |
| US-20200299273-A1 | PYRROLIDINE DERIVATIVE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2020-09-24 | — | — | US | disclosed |
| EP-3459941-A1 | PYRROLIDINE DERIVATIVE | Kissei Pharmaceutical Co., Ltd. (JP) | 2019-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299273-A1 | PYRROLIDINE DERIVATIVE | CALCRL, NPY1R, GRPR | KCNH2 292/4885SLC6A3 648/4885SCN3A 742/4885 |
| US-10995084-B2 | Pyrrolidine derivative | CALCRL, NPY1R, GRPR | KCNH2 292/4885SLC6A3 648/4885SCN3A 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.